Archive for the ‘treatments’ Category
Taltz challenges Humira in head to head clinical trial treating psoriatic arthritis
Eli Lilly and Company shared new data from its 52-week, head-to-head biologic clinical trial pitting its Taltz (ixekizumab) against AbbVie’s longtime blockbuster Humira (adalimumab) in patients with psoriatic arthritis who had not yet tried a biologic. Here’s the bottom line for those of you who just want the answers without Continue Reading…
Tremfya approval in U.S. for psoriatic arthritis looks likely
Tremfya (guselkumab), is approved by the U.S. Food and Drug Administration (FDA) and regulators elsewhere for the treatment of adults with moderate to severe plaque psoriasis. It is an IL-23 inhibitor that is very successful at improving skin psoriasis. It was approved in Europe in 2019 for active psoriatic arthritis, Continue Reading…
Company behind Humira and Skyrizi asks regulators to green-light Rinvoq for psoriatic arthritis
AbbVie, the North Chicago company behind the longtime blockbuster biologic Humira (adalimumab) and the new biologic Skyrizi (risankizumab-rzaa), has asked the U.S. Food and Drug Administration (FDA) and its European counterpart to approve its rheumatoid arthritis (RA) drug Rinvoq (upadacitinib) for psoriatic arthritis. Rinvoq is a JAK inhibitor administered as Continue Reading…
Our new “Psoriasis Journey” campaign is rolling out
Our new Psoriasis Journey campaign is rolling out now to prep for for an official June 8, 2020 launch. On that date, our volunteer patient with severe psoriasis is going to begin one of the cutting-edge psoriasis treatments we’ve been hearing so much about. You can follow along with his Continue Reading…
Want to try an experimental psoriasis treatment for your skin or scalp?
Before a doctor can prescribe a treatment, it goes through years of research and testing, including multiple rounds of clinical trials, using volunteer patients to test a potential treatment’s safety and effectiveness. The clinical trials are developed in consultation with government regulators (here, the US Food and Drug Administration, or Continue Reading…
What is ALZUMAb? It’s the psoriasis biologic no one in America has heard of
Ever heard of Enbrel? Humira? How about ALZUMAb? ALZUMAb (drug name itolizumab) is a “humanized anti-CD6 monoclonal antibody” for adults with active moderate to severe psoriasis. It has a different mechanism of action than the biologics available in the US, Europe, and Japan. It’s only available in India, where it Continue Reading…
Cosentyx goes head to head against Humira in psoriatic arthritis…it’s mostly a draw
Two biologics that work on psoriatic disease differently – Cosentyx (drug name secukinumab, an IL-17a inhibitor) and Humira (drug name adalimumab, a TNF-alpha inhibitor) – were recently tested in a study designed and funded by Novartis, the company behind Cosentyx. The study pitted Cosentyx against Humira for 52 weeks in Continue Reading…
New patient registry PsoProtect for those battling both psoriasis and COVID-19/coronavirus could help provide treatment insights to both ailments
Scientists and physicians in the UK, working with an international coalition of experts and organizations, have launched a web-based registry that will gather health information on people with psoriasis who develop confirmed or suspected COVID-19/coronavirus. The results, if enough doctors participate, could provide important information in the treatment of both Continue Reading…
Do I need to worry about links between psoriasis and Alzheimer’s disease?
You may have seen the headlines: “Psoriasis tied to higher Alzheimer’s disease risk.” Great. Just another thing to worry about thanks to psoriasis, right? But when you dig into the research, you realize it’s mostly just the usual media hype: there’s no need to panic the next time you misplace Continue Reading…
Coronavirus, COVID-19, and psoriasis: what you need to know
We are sorry, this page was moved and updated here: COVID-19, vaccination, and psoriasis: the latest in what you need to know [Last updated 10-28-2021]
